Lexicon director buys 100K shares at $1.47

Lexicon Pharmaceuticals director Raymond Debbane reported an open-market purchase of 100,000 shares of common stock at $1.47 per share.

Accepted by SEC EDGAR 02/25/2026 - 07:00 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Lexicon Pharmaceuticals director Raymond Debbane reported an open-market purchase of 100,000 shares of common stock at $1.47 per share. Following this buy, he directly holds 1,904,186 shares. The filing also lists additional indirect holdings through Avicenna Life Sci Master Fund LP and several Invus investment entities.

Insider Trade Summary

Net Buyer: 100,000 shares

Net Buy 1 txn

Insider DEBBANE RAYMOND

Role Director

Bought 100,000 shs ($147K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	100,000	$1.47	$147K
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,904,186 shares (Direct); Common Stock — 1,538,462 shares (Indirect, By Avicenna Life Sci Master Fund LP and related parties); Common Stock — 7,362,368 shares (Indirect, By Invus Public Equities, L.P. and related parties); Common Stock — 5,451,204 shares (Indirect, By Invus US Partners, LLC and related parties); Common Stock — 35,402,689 shares (Indirect, By Invus, L.P. and related parties)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lexicon (LXRX) director Raymond Debbane do in this Form 4 filing?

Raymond Debbane reported buying 100,000 Lexicon common shares in an open-market transaction at $1.47 per share. After this purchase, he directly owns 1,904,186 shares, plus additional indirect holdings through several affiliated investment entities.

How many Lexicon (LXRX) shares did Raymond Debbane buy and at what price?

He purchased 100,000 shares of Lexicon Pharmaceuticals common stock at an average price of $1.47 per share. This open-market transaction increased his direct ownership to 1,904,186 shares as of the reported transaction date of February 23, 2026.

What is Raymond Debbane’s total direct Lexicon (LXRX) ownership after the reported trade?

After the reported open-market purchase, Raymond Debbane directly owns 1,904,186 shares of Lexicon Pharmaceuticals common stock. The Form 4 also discloses separate, indirect holdings through Avicenna Life Sci Master Fund LP and multiple Invus-branded investment entities.

Does the Form 4 for Lexicon (LXRX) show any stock sales by Raymond Debbane?

The Form 4 reports an open-market purchase but no stock sales by Raymond Debbane. It lists one buy of 100,000 common shares and then updates his direct and indirect holdings, with no disposal transactions disclosed in the summarized data.

What indirect Lexicon (LXRX) holdings are reported for Raymond Debbane?

The filing lists indirect ownership of Lexicon shares through Avicenna Life Sci Master Fund LP and related parties, Invus Public Equities, L.P., Invus US Partners, LLC, and Invus, L.P. Each entity’s total share position is reported as an indirect holding associated with Debbane.

On what date did Raymond Debbane’s Lexicon (LXRX) stock purchase occur?

The reported open-market purchase of 100,000 Lexicon common shares took place on February 23, 2026. That date is the official transaction date in the Form 4, covering both the new buy and the updated post-transaction ownership amounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEBBANE RAYMOND

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD.

11TH FLOOR

(Street)

THE WOODLANDS TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		P		100,000	A	$1.47	1,904,186	D
Common Stock								1,538,462	I	By Avicenna Life Sci Master Fund LP and related parties
Common Stock								7,362,368	I	By Invus Public Equities, L.P. and related parties
Common Stock								5,451,204	I	By Invus US Partners, LLC and related parties
Common Stock								35,402,689	I	By Invus, L.P. and related parties

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Raymond Debbane	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.